Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evolus, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EOLS
Nasdaq
2834
www.evolus.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evolus, Inc.
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
- Nov 15th, 2026 7:12 pm
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov 13th, 2026 2:05 pm
Evolus (EOLS) Q3 2026 Earnings Call Transcript
- Nov 5th, 2026 9:28 am
Evolus, Inc. Q3 2026 Earnings Call Summary
- Nov 5th, 2026 6:30 am
Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ...
- Nov 5th, 2026 6:09 am
What Evolus (EOLS) Said on Its Q3 Earnings Call
- Nov 4th, 2026 7:14 pm
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
- Nov 4th, 2026 4:45 pm
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook
- Nov 4th, 2026 2:05 pm
Evolus to Participate in Upcoming Investor Conferences in New York and London
- Oct 28th, 2026 6:30 am
Evolus to Report Third Quarter Financial Results on November 4, 2026
- Oct 21st, 2026 6:30 am
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
- Oct 14th, 2026 6:30 am
UTMD Trades at a Premium to the Industry: How to Play the Stock?
- Oct 8th, 2026 11:02 am
FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action
- Oct 2nd, 2026 11:41 am
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
- Oct 1st, 2026 6:30 am
Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future
- Sep 9th, 2026 12:10 am
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
- Sep 1st, 2026 9:37 am
Telix Appoints David Gill as Chair
- Aug 31st, 2026 4:21 pm
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
- Aug 27th, 2026 7:55 am
Following Heightened Competition from Botox, Xeomin, and Long-Acting Daxxify, New Study Evaluates Dysport (abobotulinumtoxinA) Revenue Trajectory Through 2034
- Aug 17th, 2026 8:56 am
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
- Aug 11th, 2026 7:55 am
Scroll